Form 4: Crinetics Pharmaceuticals Director Stephanie Okey Executes Stock Option and Sells Shares

Director Stephanie Okey exercised stock options and sold shares of Crinetics Pharmaceuticals on March 28, 2024.

Summary

• On March 28, 2024, Stephanie Okey, a director of Crinetics Pharmaceuticals, exercised stock options to acquire 17,500 shares of common stock at a price of $18.29 per share.
• Simultaneously, Okey sold 17,500 shares of common stock in the open market at a weighted average price of $46.38 per share, with prices ranging from $46.06 to $46.66.
• Following these transactions, Okey directly owns 6,000 shares of Crinetics Pharmaceuticals common stock.
• Okey also holds options to purchase 0 shares of Crinetics Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The director exercised options and sold shares, which could be interpreted in various ways but doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.

Key Dates